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Abstract
Background: Respiratory	syncytial	virus	(RSV)‐associated	acute	lower	respiratory	in‐
fection	is	a	common	cause	for	hospitalization	and	hospital	deaths	in	young	children	
globally.	There	is	urgent	need	to	generate	evidence	to	inform	immunization	policies	
when	RSV	vaccines	become	available.	The	WHO	piloted	a	RSV	surveillance	 strat‐
egy	 that	 leverages	 the	existing	capacities	of	 the	Global	 Influenza	Surveillance	and	
Response	 System	 (GISRS)	 to	 better	 understand	RSV	 seasonality,	 high‐risk	 groups,	
validate	case	definitions,	and	develop	laboratory	and	surveillance	standards	for	RSV.
Methods: The	RSV	sentinel	surveillance	strategy	was	piloted	in	14	countries.	Patients	
across	all	age	groups	presenting	to	sentinel	hospitals	and	clinics	were	screened	all	
year‐round	using	extended	severe	acute	respiratory	infection	(SARI)	and	acute	res‐
piratory	 infection	 (ARI)	 case	definitions	 for	hospital	 and	primary	care	 settings,	 re‐
spectively.	 Respiratory	 specimens	 were	 tested	 for	 RSV	 at	 the	 National	 Influenza	
Centre	(NIC)	using	standardized	molecular	diagnostics	that	had	been	validated	by	an	
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1  | INTRODUC TION
Respiratory	syncytial	virus	 (RSV)	 is	an	 important	cause	of	 respira‐
tory	infections,	with	the	most	severe	infections	occurring	in	young	
children,	 older	 adults,	 and	 adults	 with	 chronic	 co‐morbidities.1,2 
Acute	 lower	 respiratory	 infections	 (bronchiolitis	 and	 pneumonia)	
due	to	RSV	are	among	the	most	common	causes	of	hospital	admis‐
sion	(estimated	3.2	million	annually)	and	hospital	deaths	(estimated	
59	600)	 in	 young	 children	 globally	 and	 are	 associated	with	 a	 high	
hospitalization	cost	burden.3,4	The	overall	number	of	deaths	associ‐
ated	with	RSV	is	less	certain	but	has	been	estimated	to	be	between	
94	600	and	149	400	deaths	in	young	children	globally.5	RSV	disease	
in	young	children	has	been	associated	with	persisting	sequelae	such	
as	 recurrent	 wheeze	 and	 asthma	 later	 in	 childhood.6	 The	 burden	
of	severe	disease	and	deaths	from	RSV	 in	high‐risk	adults	remains	
uncertain	but	 initial	estimates	suggest	 that	 influenza	virus	 is	more	
common	than	RSV,	but	RSV	infection	has	a	higher	risk	of	death	than	
seasonal	 influenza	 in	 adults.7	 The	RSV	vaccine	development	 land‐
scape	is	evolving	rapidly.	There	are	currently	several	vaccine	candi‐
dates	and	monoclonal	antibodies	in	various	stages	of	clinical	trials.8,9 
The	World	Health	Organization	 (WHO)	 Product	Development	 for	
Vaccines	Advisory	Committee	assessed	RSV	as	the	most	promising	
new	vaccine	of	potential	major	public	health	importance	that	may	be	
ready	for	widespread	implementation	in	the	next	10	years.10	A	gap	
analysis	 indicates	that	most	data	on	RSV	disease	symptoms,	treat‐
ment,	and	acute	sequelae	are	from	high‐income	countries	in	contrast	
to	the	RSV	burden	distribution.	RSV	disease	data	from	low‐	and	mid‐
dle‐income	countries	(LMICs)	are	improving,	but	additional	data	and	
granularity	are	needed	particularly	on	disease	in	the	first	6	months	
of	 life.11	 The	 Gavi	 Vaccine	 Alliance	 approved	 RSV	 immunization	
products	in	its	Vaccine	Investment	Strategy	for	2021‐25	contingent	
on	availability	of	a	licenced	product,	a	SAGE	recommendation,	WHO	
pre‐qualification,	and	meeting	the	financial	assumptions	used	as	the	
basis	of	the	RSV	investment	case.12	Given	the	importance	of	RSV	as	
a	significant	cause	of	hospitalization	and	death	in	young	children,	it	
is	likthat	a	cost‐effective	vaccine	would	be	considered	for	inclusion	
in	national	immunization	programs	globally.
Most	LMICs	 in	Asia	and	Africa,	where	the	RSV	disease	burden	
is	 likely	 to	be	 the	greatest,	have	 little	or	no	national	data	and	 low	
awareness	of	RSV	as	a	cause	of	disease.	Clinical	guidelines	for	the	
management	 of	 lower	 respiratory	 infections	 in	 children	 in	 LMICs	
such	 as	 the	 WHO	 Integrated	 Management	 of	 Childhood	 Illness	
(IMCI)	13	do	not	advocate	the	use	of	RSV	diagnostic	testing	as	yet	
and	 routine	 hospital	 information	 systems	 do	 not	 generally	 report	
data	on	RSV	which	can	 inform	national	 immunization	program	de‐
cision	making.	This	gap	 in	knowledge	may	 impede	evidence‐based	
policy	 decisions	with	 respect	 to	 the	 potential	 introduction	 of	 any	
new	RSV	vaccine	in	LMIC.
The	Global	Influenza	Surveillance	and	Response	System	(GISRS)	
coordinated	by	WHO	and	endorsed	by	national	governments	tests	
more	 than	 two	million	 respiratory	 specimens	 annually	 to	monitor	
the	 spread	 and	 evolution	 of	 influenza	 viruses	 through	 a	 network	
of	about	150	well‐established	 laboratories	 in	114	countries	 repre‐
senting	91%	of	 the	world's	population.	The	GISRS	network	 is	 ide‐
ally	placed	as	a	platform	for	the	introduction	of	a	more	systematic	
testing	for	RSV	associated	with	respiratory	illness	as	it	already	uses	
molecular	 diagnostics	 on	 respiratory	 specimens	 and	 conditioned	
to	 report	 regular	 and	 disciplined	 reporting	 to	 a	 global	 platform.	
Countries	 in	Latin	America	and	 the	Caribbean	 region	started	 test‐
ing	for	RSV	by	immunofluorescence.	As	RSV	molecular	diagnostics	
became	widely	available,	many	countries	within	the	GISRS	started	
testing	for	RSV	and	other	respiratory	viruses	as	a	by‐product	of	in‐
fluenza	 surveillance	 using	 the	 WHO‐recommended	 influenza‐like	
illness	(ILI),	acute	respiratory	infection	(ARI),	and	severe	acute	respi‐
ratory	infection	(SARI)	case	definitions	(Table	1).	However,	the	use	
of	case	definitions	primarily	meant	for	influenza	surveillance	and	a	
lack	of	standardized	testing	protocols	for	RSV	were	likely	to	provide	
biased	results.	A	WHO	consultative	meeting	of	 influenza	and	RSV	
experts	in	2015	proposed	to	leverage	GISRS	as	a	cost‐effective,	af‐
fordable,	and	sustainable	platform	for	RSV	surveillance	to	generate	
policy‐actionable	data	on	RSV	in	advance	of	new	RSV	vaccines	be‐
coming	available.14	The	WHO	Global	Influenza	Program	developed	
a	strategy	for	RSV	surveillance	based	on	GISRS	that	was	rolled	out	
as	a	3‐year	pilot	project	in	14	countries	(Argentina,	Australia,	Brazil,	
External	Quality	Assurance	program.	The	WHO	FluMart	data	platform	was	adapted	
to	receive	case‐based	RSV	data	and	visualize	interactive	visualization	outputs.
Results: Laboratory	standards	for	detecting	RSV	by	RT‐PCR	were	developed.	A	review	
assessed	the	feasibility	and	the	low	incremental	costs	for	RSV	surveillance.	Several	
challenges	were	addressed	related	to	case	definitions,	sampling	strategies,	the	need	
to	focus	surveillance	on	young	children,	and	the	data	required	for	burden	estimation.
Conclusions: There	was	no	evidence	of	any	significant	adverse	impact	on	the	func‐
tioning	of	GISRS	which	is	primarily	intended	for	virologic	and	epidemiological	surveil‐
lance	of	influenza.
K E Y W O R D S
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Canada,	Chile,	Côte	d’Ivoire,	Egypt,	 India,	Mongolia,	Mozambique,	
Russian	Federation,	Thailand,	South	Africa,	and	United	Kingdom	of	
Great	Britain	and	Northern	Ireland)	across	the	six	WHO	regions	in	
2017‐18.15	These	countries	were	selected	 in	consultation	with	the	
WHO	regional	offices	based	on	existing	and	strong	capacities	in	lab‐
oratory	and	epidemiological	surveillance	and	willingness	to	partici‐
pate	in	the	pilot.	The	overall	aim	of	the	pilot	was	to	investigate	the	
suitability	of	the	GISRS	platform	for	RSV	surveillance	in	a	range	of	
settings.	This	paper	describes	the	strategy	and	discusses	how	vari‐
ous	epidemiological	and	laboratory	challenges	were	addressed.
2  | PILOTING THE STR ATEGY FOR RSV 
SURVEILL ANCE
The	 overall	 strategy	 aimed	 to	 leverage	 and	 build	 on	 the	 existing	
capacities	 of	 the	 well‐established	 GISRS	 to	 test	 for	 RSV	 without	
adversely	affecting	its	vital	role	in	influenza	surveillance.15	The	con‐
tinuing	commitment	by	governments	to	GISRS	would	facilitate	the	
extension	to	ownership	and	sustainability	of	RSV	in	national	disease	
surveillance	in	addition	to	influenza.	The	primary	aim	of	establishing	
RSV	surveillance	was	to	better	understand	the	epidemiological	and	
virologic	features	of	RSV	circulation	in	a	wide	range	of	settings	and	
generate	evidence	on	seasonality,	high‐risk	groups,	and	disease	bur‐
den	to	inform	potential	introduction	of	new	RSV	vaccines.	The	pilot	
project	was	also	built	to	evaluate	the	performance	of	new	case	defi‐
nitions	for	RSV	surveillance,	develop	global	laboratory,	epidemiolog‐
ical	and	reporting	standards	for	RSV	surveillance,	assess	incremental	
surveillance	and	laboratory	costs,	and	finally	test	the	feasibility	and	
evaluate	any	adverse	impact	on	GISRS.
Three	 designated	 reference	 laboratories	 (Respiratory	 Viruses	
Branch,	Division	of	Viral	Diseases,	Centers	for	Disease	Control	and	
Prevention	 (CDC),	 United	 States;	 Public	 Health	 England,	 United	
Kingdom	 of	Great	 Britain	 and	Northern	 Ireland;	 and	 the	National	
Institute	 of	 Communicable	Diseases,	 South	 Africa)	 participated	 in	
the	 Quality	 Control	 for	 Molecular	 Diagnostics	 (QCMD)	 external	
quality	assurance	program	for	RSV.	The	National	Influenza	Centres	
(NICs)	 successfully	participated	 in	proficiency	 testing	using	panels	
developed	by	CDC	containing	both	contemporary	clades	and	past	
lineages	of	RSV.	The	NICs	worked	in	conjunction	with	their	disease	
control	programs	in	fourteen	countries	 (two	or	three	from	each	of	
the	six	WHO	regions)	spread	across	both	hemispheres	(Figure	1),	to	
screen	patients	in	all	age	groups	all	year‐round,	using	extended	SARI	
and	ARI	case	definitions	 (Table	1)	at	 sentinel	hospitals	and	clinics,	
respectively	 (Figure	 2).	 Respiratory	 specimens	were	 collected	 and	
transported	 according	 to	WHO	 guidelines	 16	 and	 batch‐tested	 at	
the	NIC	using	a	standardized	real‐time	RT‐PCR	assay	developed	by	
CDC	and	validated	against	commonly	used	RNA	extraction	systems	
and	 amplification	platforms.	 The	NICs	 had	 the	option	of	 using	 ei‐
ther	a	commercial	or	an	in‐house	developed	RT‐PCR	assay	provided	
it	 had	been	validated	against	 the	CDC	assay.	The	use	of	 enzymes	
and	reagents	for	the	RT‐PCR	assay	were	standardized	and	supplied	
by	the	International	Reagents	Resource,	CDC.	The	designated	RSV	
reference	 laboratories	 provided	 technical	 and	 training	 support	 to	
the	NICs	on	request.	The	WHO	FluMart	data	reporting	platform	for	
influenza	was	adapted	for	countries	to	directly	upload	anonymized	
case‐based	RSV	data	using	 their	 own	database	 structure	 and	 sys‐
tem	without	having	to	transform	it.	Interactive	data	visualization	of	
trends,	distributions,	and	other	outputs	were	developed	that	could	
be	 stratified	 by	 country,	 year,	 period,	 age,	 hospital	 or	 outpatient‐
based	 surveillance,	 and	presence	or	 absence	of	 fever.	An	external	
advisory	group	provided	oversight	to	the	pilot	project.
3  | OPPORTUNITIES AND CHALLENGES
The	RSV	 surveillance	 strategy	 aims	 to	 leverage	existing	national	 re‐
sources	 of	 the	 GISRS	 without	 adversely	 impacting	 its	 established	
TA B L E  1  WHO‐recommended	case	definitions	for	RSV	and	influenza	surveillance
 RSV Influenza
Hospital‐based Extended	SARI
•	 onset	within	past	10	d
•	 cough	(cough	or	shortness	of	breath)
In infants less than 6 mo age
•	 Apnea	(temporary	cessation	of	breathing	from	any	cause)
•	 Sepsis
o	 fever	more	than	37.5°C	or	hypothermia
o	 shock	(lethargy,	fast	breathing,	cold	skin,	prolonged	capillary	refill,	
or	weak	pulse),	and
o	 seriously	ill	without	apparent	cause
SARI
•	 onset	within	past	10	d
•	 cough	(cough	or	shortness	of	breath)
•	 history	of	fever	or	measured	fever	of	38°C	
or more
Community‐based ARI
•	 sudden	onset
•	 At	least	one	of
•	 cough
•	 sore	throat
•	 shortness	of	breath
•	 coryza
ILI
•	 onset	within	past	10	d
•	 measured	fever	of	38°C	or	more,	and
•	 cough
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activities.	The	primary	focus	on	hospital‐based	surveillance,	to	ascer‐
tain	more	severe	RSV	infections,	and	on	younger	age	groups,	that	are	
likely	to	be	a	key	group	driving	vaccine	policy	decisions,	placed	some	
important	practical	demands	on	 the	pilot.	The	need	 to	evaluate	 the	
performance	of	the	extended	SARI	and	ARI	case	definitions	proposed	
for	RSV	surveillance	required	gathering	case‐based	clinical	data	in	ad‐
dition	to	routine	surveillance	data.	However,	 it	was	not	practical	 for	
detailed	patient	data	to	be	collected	in	the	pilot	for	a	comprehensive	
clinical	description	of	hospitalized	RSV	disease,	nor	could	robust	data	
be	collected	on	population‐based	RSV	disease	burden	or	disease	costs.
F I G U R E  1  Countries	participating	in	the	WHO	global	RSV	surveillance
F I G U R E  2  Algorithm	for	selection	of	
patients	for	testing	for	RSV
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3.1 | Opportunities presented by the pilot
The	 pilot	 gave	 the	 opportunity	 to	 gather	 policy‐relevant	 data	 on	
RSV	with	a	relatively	low‐cost	approach,	building	on	the	established	
GISRS	platform.	When	effective	RSV	interventions	become	availa‐
ble,	the	data	gathered,	together	with	the	estimates	of	economic	and	
population	burden	of	RSV,	will	enable	Ministries	of	Health	to	make	
evidence‐based	decisions	on	vaccine	implementation	and	to	monitor	
the	impact	of	vaccination	programs.	This	will	have	the	added	benefit	
that	national	 support	 to	GISRS	 is	maintained	and	 increased.	Thus,	
the	pilot	represents	an	opportunity	to	influence	emerging	ideas	on	
RSV	surveillance	and	establish	global	guidelines	and	best	practice.
Virologic	surveillance	 in	 the	 future	will	allow	for	monitoring	of	
any	genetic	drift	and	its	relationship	to	antigenic	change.	These	data	
could	be	used	 to	 identify	 escape	mutants	 and	assess	 the	possible	
impact	 of	 genetic	 changes	 on	 virulence	 or	 vaccine	 or	monoclonal	
efficacy.	Work	to	develop	capability	and	demonstration	of	the	fea‐
sibility	of	generating	high‐quality	RSV	sequence	data	could	have	im‐
portant	utility	in	responding	to	future	calls	for	data	after	vaccine	or	
monoclonal	antibody	introduction.
The	RSV	surveillance	pilot	has	demonstrated	a	strong	case	 for	
linking	RSV	and	influenza	surveillance	systems	with	mutual	benefits.	
Extension	of	surveillance	to	additional	pediatric	sites	and	age	groups	
should	result	in	important	benefits	to	influenza	surveillance	as	this	
group	 is	 currently	 underrepresented	 in	 GISRS	 data.	 Attention	 to	
data	quality	and	completeness	should	also	yield	general	benefits	to	
GISRS.	Combined	RSV	and	influenza	surveillance	data	also	have	the	
potential	to	increase	the	value	of	GISRS	by	generating	data	on	RSV	
and	influenza	co‐infections	and	 improving	the	certainty	of	vaccine	
effectiveness	estimates	for	influenza,	for	which	RSV	disease	presen‐
tation	may	be	a	clinical	confounder.	In	the	future,	this	platform	could	
serve	as	a	basis	for	a	more	broad‐based	surveillance	of	respiratory	
pathogens.
Respiratory	 syncytial	 virus	 surveillance	may	 not	 yield	 detailed	
and	robust	burden	of	disease	estimates	in	many	LMICs.	Nevertheless,	
national	policymakers	should	still	find	estimates	of	RSV‐associated	
hospitalizations	 useful	 in	 guiding	 policy	 in	 the	 absence	of	 popula‐
tion‐based	burden	data.	The	pilot	gave	the	opportunity	to	produce	
policy‐relevant	RSV	disease	morbidity	estimates	and	improve	under‐
standing	of	RSV	seasonality	and	of	global	RSV	virologic	patterns—all	
of	which	will	be	of	programmatic	value	in	future	national,	regional,	
and	global	control	programs.
Advocacy	tools	and	approaches	developed	in	the	pilot,	to	raise	
awareness	of	RSV	among	the	government,	medical	profession,	and	
community,	can	be	used	in	future	communications,	for	example,	to	
communicate	the	importance	of	 influenza	in	different	settings	and	
age	groups.
3.2 | Epidemiology‐related challenges
Five	major	epidemiological	concerns	were	identified	for	using	GISRS	
for	RSV	surveillance.	First,	an	ILI,	ARI,	or	SARI	case	definition	that	
requires	 fever	 would	 have	 low	 sensitivity	 to	 detect	 RSV,	 as	 over	
half	of	young	children	with	RSV	infection	present	without	fever.17,18 
Furthermore,	non‐respiratory	presentations	of	RSV	infection	in	very	
young	infants	are	recognized	(apnea,	sepsis	with	no	apparent	cause)	
and	a	wider	case	definition	would	be	needed	in	this	age	group.19,20 
The	pilot	addressed	 this	concern	by	using	extended	SARI	and	ARI	
case	definitions	(which	do	not	include	fever)	for	hospital‐based	and	
community‐based	 surveillance,	 respectively.	 In	 addition,	 the	 case	
definition	 for	 infants	aged	 less	 than	6	months	 included	apnea	and	
sepsis	 from	 undetermined	 cause	 (Table	 1).	 Second,	 the	 RSV	 dis‐
ease	burden	is	highest	 in	children	aged	 less	than	2	years,21	an	age	
group	historically	underrepresented	in	influenza	surveillance	by	the	
GISRS.	The	pilot	addressed	 this	 concern	with	quota	 sampling	 that	
required	each	country	to	recruit	and	test	1000	eligible	patients	per	
year	 (about	20	per	week)	stratified	equally	across	four	age	groups	
viz.	less	than	6	months,	6	months	to	less	than	5	years,	5	to	less	than	
65	years,	and	65	years	and	above.	This	would	allow	an	RSV	preva‐
lence	of	5%‐10%	to	be	detected	with	a	95%	confidence	interval	 in	
each	of	the	age	groups.	Countries	were	encouraged	to	add	pediatric	
wards	and	hospitals,	and	neonatal	and	pediatric	intensive	care	units	
to	their	existing	GISRS	sentinel	sites.	Third,	RSV	seasonality	 is	not	
fully	understood	globally.	Even	where	it	is,	seasonality	may	vary	year	
to	year	and	differ	in	timing	from	that	of	influenza	22‐24;	thus,	GISRS	
sampling	confined	to	the	influenza	season	may	miss	many	RSV	cases.	
The	pilot	addressed	this	concern	through	year‐round	surveillance	for	
RSV	in	contrast	to	influenza	surveillance	which	in	some	countries	is	
restricted	to	the	influenza	season.	Fourth,	estimation	of	the	popula‐
tion‐based	burden	from	severe	RSV	disease	requires	knowledge	of	
the	denominator	population	from	which	cases	are	drawn.	This	was	
not	available	for	most	sites	included	in	the	pilot.	However,	countries	
were	 encouraged	 to	 gather	 data	 on	 all‐cause	 hospital	 admissions,	
and	hospitalizations	 for	 respiratory	disease,	which	provides	an	es‐
timate,	of	the	contribution	of	RSV	to	the	hospital	burden	of	disease.	
In	addition,	countries	were	requested,	where	possible,	 to	estimate	
hospital	catchment	populations	required	for	estimating	population‐
based	burden.15,25	Fifth,	the	pilot	aimed	to	estimate	the	number	of	
hospitalizations	associated	with	RSV	at	each	surveillance	site.	These	
data	would	indicate	the	hospital	burden	of	RSV	at	that	surveillance	
site	and	serve	to	estimate	the	proportional	contribution	of	RSV‐asso‐
ciated	hospitalization	to	all‐cause	hospitalization.	The	total	number	
of	all‐cause	and	respiratory	or	SARI	hospital	admissions	would	gen‐
erally	be	available.	However,	the	number	of	extended	SARI	hospital	
admissions	may	not	be	routinely	available	to	estimate	the	proportion	
of	extended	SARI	patients	included	in	the	pilot.	The	assumption	that	
recruited	patients	are	the	same	as	non‐recruited	patients	may	not	be	
true	and	hence	may	produce	biased	estimates	of	the	RSV‐associated	
hospital	burden.	An	alternate	approach	could	be	to	count	the	num‐
ber	of	respiratory	admissions	that	needed	to	be	screened	over	the	
same	period	to	identify	the	number	of	extended	SARI	patients	who	
were	tested.	This	would	give	the	proportion	of	all	respiratory	admis‐
sions	 that	are	 identified	as	extended	SARI	patients	and	 tested	 for	
RSV.	This	sampling	fraction	could	then	be	used	to	adjust	the	number	
of	extended	SARI	patients	who	were	tested	and	were	positive	to	give	
an	estimate	of	the	total	number	of	RSV‐associated	hospitalizations	
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at	the	sentinel	site.	Ideally,	the	sampling	fraction	would	be	specified	
for	each	week,	age	group,	and	sentinel	surveillance	site.	For	surveil‐
lance	 sites	where	 catchment	population	estimates	 are	 available,	 it	
may	be	possible	to	estimate	population‐based	denominators	for	se‐
vere	RSV	disease	burden.25
3.3 | Laboratory‐related challenges
Three	 major	 laboratory‐related	 concerns	 were	 considered.	 First,	
most	NICs	were	already	testing	for	RSV	and	other	respiratory	viruses	
using	 commercial	 or	 laboratory‐developed	 molecular	 diagnostics,	
either	 monoplex	 or	 multiplex	 RT‐PCR	 assays	 as	 well	 as	 antigen‐
based	 testing	 methods	 that	 varied	 in	 sensitivity	 and	 specificity.	
Laboratories	in	Latin	America	were	using	direct	or	indirect	immuno‐
fluorescence	assay	(IFA)	to	detect	RSV,	the	sensitivity	and	specificity	
of	which	varies	with	the	age	of	the	patient,	and	type	and	quality	of	
specimen.	The	sensitivity	of	IFA	might	be	low	for	RSV	detection	es‐
pecially	in	the	off‐season	period.26,27	All	laboratories	agreed	to	use	
real‐time	RT‐PCR	for	RSV	detection.	Although	most	switched	to	the	
CDC	monoplex	RT‐PCR	assay,	a	few	laboratories	opted	to	continue	
using	 commercial	 or	 other	 laboratory‐developed	 RT‐PCR	 assays	
after	 validation	 against	 the	CDC	assay.	 Second,	 though	 important	
to	collect	information	on	the	circulating	RSV	strain	(A	or	B)	to	better	
understand	their	association	with	disease	severity,28‐30	the	decision	
to	type	RSV	was	left	to	the	individual	laboratories,	depending	upon	
their	available	resources	and	expertise.	Third,	 the	decision	to	con‐
duct	genome	sequencing	of	RSV	was	deferred	 to	a	 later	phase	 to	
prioritize	establishing	a	surveillance	system	for	RSV	detection	during	
the	pilot	phase,	and	to	better	define	the	goals	of	virologic	surveil‐
lance	of	RSV.
4  | DISCUSSION
The	overarching	aim	of	the	pilot	was	to	build	on	the	successful	global	
influenza	 surveillance	 platform,	GISRS,	 to	 obtain	RSV	 surveillance	
data	without	having	a	negative	impact	on	GISRS.	The	primary	moti‐
vation	was	to	establish	systems	to	obtain	data	to	inform	policy	and	
decision	making	for	possible	future	RSV	vaccine	investment,	espe‐
cially	in	LMIC	settings	in	which	it	may	be	unlikely	that	there	will	be	
other	relevant	sources	of	suitable	RSV	data	for	this	purpose.	A	mid‐
term	review	assessed	that	it	was	feasible	to	leverage	GISRS	for	RSV	
surveillance	with	little	incremental	cost	without	any	significant	ad‐
verse	impact	on	the	functioning	of	GISRS	for	influenza	surveillance.
We	have	outlined	the	major	challenges	faced,	and	the	decisions	
made	 to	 tackle	 these	 in	 the	development	of	 the	RSV	surveillance	
pilot	 approach.	 The	 pilot	 collected	 data	 to	 monitor	 performance	
at	 each	 site	 and	will	 be	 able	 to	 report	 on	 the	 degree	 of	 success	
achieved	using	 the	 approach	 adopted.	 For	 example,	 the	pilot	will	
report	on	the	relative	performance	of	the	case	definitions	for	the	
identification	 of	RSV	 and	 influenza	 cases	 in	 hospital	 and	 primary	
care	settings	and	will	monitor	the	success	 in	recruitment	of	cases	
in	the	specific	targeted	high‐risk	groups.	A	limitation	of	the	current	
pilot	 is	that	 it	did	not	specifically	target	pregnant	women	for	RSV	
surveillance.	 Although	 two	 studies	 from	 Nepal	 and	 South	 Africa	
have	 reported	 that	 RSV	 infection	 during	 pregnancy	 does	 not	 ad‐
versely	affect	the	pregnancy	outcomes	nor	that	post‐partum	RSV	
infection	of	neonates	 cause	 severe	disease,31	RSV	 surveillance	 in	
pregnant	women	should	be	considered	for	 inclusion	 in	some	sites	
in	future	extensions	of	the	global	pilot.	An	important	additional	re‐
source	required	(beyond	that	for	GISRS)	is	the	ability	to	report	data	
from	individual	cases.	This	will	help	assess	the	validity	of	changes	
to	the	surveillance	case	definitions	adopted	and	will	help	describe	
atypical	case	presentations,	for	example,	in	older	adults	and	infants.	
This	should	help	guide	future	decisions	about	how	future	RSV	sur‐
veillance	should	be	conducted	and	inform	the	design	of	studies	of	
vaccine	effectiveness.	Initial	feedback	suggests	that	many	sites	will	
have	to	expand	their	existing	GISRS	hospital	surveillance	to	include	
more	pediatric	hospitals,	and	those	that	admit	neonates	and	young	
infants	so	that	this	important	risk	group	is	adequately	represented.	
Enhanced	data	on	respiratory	support	required	during	hospitaliza‐
tion	 will	 also	 assist	 in	 assessment	 of	 the	 health	 costs	 associated	
with	 RSV.	 These	 data	will	 be	 important	 in	 health	 economical	 as‐
sessments	of	any	intervention	(such	as	vaccines).	Equally,	it	will	be	
important	to	raise	awareness	of	the	possibility	of	RSV	infection	in	
causing	 the	 respiratory	 disorders	 in	 older	 adults	 and	 those	 with	
chronic	medical	conditions.
Once	 RSV	 seasonality	 is	 better	 defined,	 it	may	 be	 possible	 to	
limit	site‐specific	surveillance	to	high	transmission	seasons	for	both	
RSV	and	influenza.	Once	RSV	case	definitions	have	been	evaluated,	
the	 need	 for	 ongoing	 individual	 case	 data	 will	 be	 reconsidered.	
Multiyear	 data	 from	RSV	 surveillance	will	 allow	 the	 study	of	 evo‐
lutionary	changes	in	RSV	over	time	and	in	response	to	widespread	
vaccine	introduction.
An	important	aspect	of	the	pilot	is	the	collection	of	surveillance	
data	on	RSV	and	influenza	in	both	primary	and	secondary	care	set‐
tings.	This	 is	 important	as	 coinfection	 in	 causation	of	 lower	 respi‐
ratory	infections	is	increasingly	recognized.32	This	joint	surveillance	
will	help	improve	knowledge	of	RSV	and	influenza	global	transmis‐
sion	patterns	and	will	 inform	future	considerations	of	the	need	for	
and	feasibility	of	broader	 infectious	disease	surveillance	platforms	
which	could	encompass	several	other	important	respiratory	patho‐
gens	that	can	result	in	hospitalization.
A	major	advantage	of	using	the	existing	GISRS	platform	is	that	
GISRS	 has	 built	 close	 relationships	 with	Ministries	 of	 Health	 and	
policymakers	 in	 individual	countries.	This	 is	clearly	signaled	by	the	
financial	support	to	the	RSV	surveillance	pilot	provided	by	national	
GISRS	platforms.	The	pilot	served	to	strengthen	these	relationships	
by	 providing	 policymakers	 with	 information	 on	 RSV	 from	 which	
vaccine	 investment,	healthcare	planning	decision,	and	cost‐benefit	
analyses	can	be	made	in	the	future.	We	expect	that	these	data	raise	
awareness	of	RSV	as	one	of	the	most	common	causes	of	hospital‐
ization	in	young	children	globally	and	an	underappreciated	cause	of	
disease	in	older	adults.	We	will	work	closely	with	other	stakehold‐
ers	in	each	country	to	ensure	that	these	data	are	presented	to	the	
appropriate	audiences	and	 respond	 to	 local	 comments	 and	needs.	
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Another	 possible	 approach	 to	 long‐term	 sustainability	 may	 be	 to	
integrate	 this	 surveillance	within	a	broader	 (respiratory)	 infectious	
disease	 surveillance	platform	 in	 secondary	 care	 that	 encompasses	
important	 infectious	 agents	 in	 a	 cost‐effective	manner.	 The	 long‐
term	sustainability	of	RSV	surveillance	will	depend	on	the	success	of	
relationships	with	the	Expanded	Program	of	Immunization	and	the	
Maternal,	Neonatal	and	Child	Health	programs	responsible	for	deliv‐
ering	RSV	immunization	products.
The	pilot	 project	 should	help	define	 the	minimum	dataset	 and	
minimum	surveillance	effort	 required	 to	maintain	a	 functional	and	
useful	RSV	surveillance,	in	a	cost‐efficient	manner	and	without	ad‐
versely	 impacting	 on	 essential	 influenza	 surveillance.	 Information	
obtained	should	also	help	 in	better	understanding	 the	 relative	 im‐
portance	 of	 RSV	 as	 a	 cause	 of	 healthcare	 burden	 in	 various	 risk	
groups	and	 the	overlap	between	 influenza	and	RSV	viral	 infection	
globally.	 It	 is	hoped	 that	experience	 from	 this	pilot	will	 serve	as	 a	
basis	 from	which	to	plan	future	RSV	surveillance	activities.	Future	
extensions	of	the	pilot	could	include	incorporating	additional	high‐
risk	groups,	such	as	pregnant	women,	and	extending	the	global	scale	
of	RSV	surveillance	so	that	global	transmission	patterns	and	season‐
ality	can	be	better	studied.
Finally,	the	pilot	phase	did	not	track	mortality	or	focus	on	sever‐
ity	of	illness	and	did	not	follow	up	subjects	for	long‐term	sequelae	
such	 as	 wheeze	 or	 asthma,	 or	 conduct	 surveillance	 in	 pregnant	
women	to	assess	the	impact	of	RSV	infection	on	pregnancy	and	birth	
outcomes,	which	could	be	a	limitation	or	an	opportunity	to	explore,	
when	RSV	surveillance	is	established	using	lessons	learnt	from	the	
pilot	phase.
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